Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03759288
Registration number
NCT03759288
Ethics application status
Date submitted
20/11/2018
Date registered
29/11/2018
Date last updated
21/11/2023
Titles & IDs
Public title
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
Query!
Scientific title
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In)
Query!
Secondary ID [1]
0
0
#3150-301-008
Query!
Secondary ID [2]
0
0
D5271C00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
INTREPID
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
IBD
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Brazikumab low dose
Treatment: Drugs - Brazikumab high dose
Treatment: Drugs - Humira®
Treatment: Drugs - Placebo
Experimental: (Stage 1) Brazikumab high dose - Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Experimental: (Stage 1) Brazikumab low dose - Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Placebo comparator: (Stage 1) Placebo - Intravenous placebo on Days 1, 29, and 57, followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
Experimental: (Stage 2) Brazikumab high dose - Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Experimental: (Stage 2) Brazikumab low dose - Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous on Day 85 and every 4 weeks through Week 48
Active comparator: (Stage 2) Humira® - Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50
Treatment: Drugs: Brazikumab low dose
Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Treatment: Drugs: Brazikumab high dose
Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
Treatment: Drugs: Humira®
Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
Treatment: Drugs: Placebo
Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Stage 1. Percentage of patients with CDAI remission
Query!
Assessment method [1]
0
0
CDAI remission is defined as achieving the CDAI score below 150 (measured by PRO questionnaire and objective items (i.e. weight, hematocrit)).
Query!
Timepoint [1]
0
0
at Week 12
Query!
Primary outcome [2]
0
0
Stage 2. Percentage of patients with endoscopic response
Query!
Assessment method [2]
0
0
Endoscopic response is described as minimum of 50% decrease from Baseline in SES-CD total score.
Query!
Timepoint [2]
0
0
at Week 52
Query!
Primary outcome [3]
0
0
Stage 2. Percentage of patients with clinical remission
Query!
Assessment method [3]
0
0
Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item (measured by PRO questionnaire).
Query!
Timepoint [3]
0
0
at Week 52
Query!
Secondary outcome [1]
0
0
Stage 1. Percentage of patients with endoscopic response
Query!
Assessment method [1]
0
0
Endoscopic response is described as minimum of 50% decrease from Baseline in SES-CD total score.
Query!
Timepoint [1]
0
0
at Week 12
Query!
Secondary outcome [2]
0
0
Stage 1. Percentage of patients with clinical remission
Query!
Assessment method [2]
0
0
Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item (measured by PRO questionnaire).
Query!
Timepoint [2]
0
0
at Week 12
Query!
Secondary outcome [3]
0
0
Stage 1. Percentage of patients with CDAI response
Query!
Assessment method [3]
0
0
CDAI response is defined as achieving the CDAI score of \< 150 points or CDAI reduction from Baseline of = 100 points (measured by PRO questionnaire and objective items (i.e. weight, hematocrit)).
Query!
Timepoint [3]
0
0
at Week 12
Query!
Secondary outcome [4]
0
0
Stage 1. Percentage of patients with CDAI remission
Query!
Assessment method [4]
0
0
CDAI remission is defined as achieving the CDAI score below 150 (measured by PRO questionnaire and objective items (i.e. weight, hematocrit)).
Query!
Timepoint [4]
0
0
at both Week 12 and Week 52
Query!
Secondary outcome [5]
0
0
Stage 1. Percentage of patients with CDAI response
Query!
Assessment method [5]
0
0
CDAI response is defined as achieving the CDAI score of \< 150 points or CDAI reduction from Baseline of = 100 points (measured by PRO questionnaire and objective items (i.e. weight, hematocrit)).
Query!
Timepoint [5]
0
0
at both Week 12 and Week 52
Query!
Secondary outcome [6]
0
0
Stage 1. Percentage of patients with endoscopic response
Query!
Assessment method [6]
0
0
Endoscopic response is described as minimum of 50% decrease from Baseline in SES-CD total score.
Query!
Timepoint [6]
0
0
at both Week 12 and Week 52
Query!
Secondary outcome [7]
0
0
Stage 1. Percentage of patients with clinical remission
Query!
Assessment method [7]
0
0
Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item (measured by PRO questionnaire).
Query!
Timepoint [7]
0
0
at both Week 12 and Week 52
Query!
Secondary outcome [8]
0
0
Stage 1. Percentage of patients with endoscopic remission
Query!
Assessment method [8]
0
0
Endoscopic remission is defined as achieving the SES-CD total score of 0-2 OR SES-CD total score of = 4 and at least 2 point reduction from Baseline with no subscore \> 1
Query!
Timepoint [8]
0
0
at Week 52
Query!
Secondary outcome [9]
0
0
Stage 1. Percentage of patients with clinical remission
Query!
Assessment method [9]
0
0
Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item (measured by PRO questionnaire).
Query!
Timepoint [9]
0
0
at Week 52
Query!
Secondary outcome [10]
0
0
Stage 1. Percentage of patients with CDAI response
Query!
Assessment method [10]
0
0
CDAI response is defined as achieving the CDAI score of \< 150 points or CDAI reduction from Baseline of = 100 points (measured by PRO questionnaire and objective items (i.e. weight, hematocrit)).
Query!
Timepoint [10]
0
0
at Week 52
Query!
Secondary outcome [11]
0
0
Stage 1. Percentage of patients with CDAI remission
Query!
Assessment method [11]
0
0
CDAI remission is defined as achieving the CDAI score below 150 (measured by PRO questionnaire and objective items (i.e. weight, hematocrit)).
Query!
Timepoint [11]
0
0
at Week 52
Query!
Secondary outcome [12]
0
0
Stage 1. Percentage of patients with endoscopic response
Query!
Assessment method [12]
0
0
Endoscopic response is described as minimum of 50% decrease from Baseline in SES-CD total score.
Query!
Timepoint [12]
0
0
at Week 52
Query!
Secondary outcome [13]
0
0
Stage 1. Percentage of patients with SES-CD total score of 0-2
Query!
Assessment method [13]
0
0
SES-CD total score of 0-2
Query!
Timepoint [13]
0
0
at Week 52
Query!
Secondary outcome [14]
0
0
Stage 1. Percentage of patients with endoscopic response and endoscopic remission
Query!
Assessment method [14]
0
0
Endoscopic response: Minimum of 50% decrease from Baseline in SES-CD total score Endoscopic remission: SES-CD total score of 0-2, OR - SES-CD total score of = 4 and at least 2 point reduction from Baseline with no subscore \> 1
Query!
Timepoint [14]
0
0
Endoscopic response at Week 12, endoscopic remission at Week 52
Query!
Secondary outcome [15]
0
0
Stage 1. Serum concentration of brazikumab
Query!
Assessment method [15]
0
0
Pharmacokinetics: concentration of brazikumab in serum
Query!
Timepoint [15]
0
0
Through Week 68
Query!
Secondary outcome [16]
0
0
Stage 1. Incidence of anti-drug antibodies
Query!
Assessment method [16]
0
0
Immunogenicity: incidence of brazikumab anti-drug antibodies in serum
Query!
Timepoint [16]
0
0
Through Week 68
Query!
Secondary outcome [17]
0
0
Stage 1. Exposure-response
Query!
Assessment method [17]
0
0
Derive exposure response model linking primary endpoint to metrics of model predicted individual brazikumab exposures
Query!
Timepoint [17]
0
0
Through Week 68
Query!
Secondary outcome [18]
0
0
Stage 1. Serum IL-22 concentration clinical cutoff for Stage 2
Query!
Assessment method [18]
0
0
Derive the relationship between baseline serum IL-22 concentration and efficacy of brazikumab through CDAI remission and endoscopic response
Query!
Timepoint [18]
0
0
at Week 12
Query!
Secondary outcome [19]
0
0
Stage 1. Number and percentage of patients with adverse events
Query!
Assessment method [19]
0
0
Number and percentage of patients with reported adverse events.
Query!
Timepoint [19]
0
0
Through Week 68
Query!
Secondary outcome [20]
0
0
Stage 1. Percentage of patients with potentially clinically significant changes in laboratory values
Query!
Assessment method [20]
0
0
Percentage of patients with clinically significant changes in hematology, clinical chemistry, urinalysis.
Query!
Timepoint [20]
0
0
Through Week 68
Query!
Secondary outcome [21]
0
0
Stage 1. Percentage of patients with potentially clinically significant changes in vital signs
Query!
Assessment method [21]
0
0
Percentage of patients with potentially clinically significant changes in systolic, diastolic pulse rate.
Query!
Timepoint [21]
0
0
Through Week 68
Query!
Secondary outcome [22]
0
0
Stage 1. Percentage of patients with potentially clinically significant changes in physical exams
Query!
Assessment method [22]
0
0
Percentage of patients with potentially clinically significant changes in full physical exams.
Query!
Timepoint [22]
0
0
Through Week 68
Query!
Secondary outcome [23]
0
0
Stage 1. Percentage of patients with potentially clinically significant changes in ECGs
Query!
Assessment method [23]
0
0
Percentage of patients with potentially clinically significant changes in 12-lead ECG recordings
Query!
Timepoint [23]
0
0
Through Week 68
Query!
Secondary outcome [24]
0
0
Stage 2. Percentage of patients with endoscopic response
Query!
Assessment method [24]
0
0
Endoscopic response is described as minimum of 50% decrease from Baseline in SES-CD total score
Query!
Timepoint [24]
0
0
at both Week 12 and Week 52
Query!
Secondary outcome [25]
0
0
Stage 2. Percentage of patients with clinical remission
Query!
Assessment method [25]
0
0
Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item (measured by PRO questrionare)
Query!
Timepoint [25]
0
0
at both Week 12 and Week 52
Query!
Secondary outcome [26]
0
0
Stage 2: Percentage of patients with endoscopic remission
Query!
Assessment method [26]
0
0
Endoscopic remission: - SES-CD total score of 0-2, OR - SES-CD total score of = 4 and at least 2 point reduction from Baseline with no subscore \> 1
Query!
Timepoint [26]
0
0
at Week 52
Query!
Secondary outcome [27]
0
0
Stage 2. Percentage of patients with clinical remission
Query!
Assessment method [27]
0
0
Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item (measured by PRO questrionare)
Query!
Timepoint [27]
0
0
at Week 52
Query!
Secondary outcome [28]
0
0
Stage 2: Percentage of patients with CS-free endoscopic remission
Query!
Assessment method [28]
0
0
Percentage of patients achieving Endoscopic remission and are CS-free where endoscopic remission is defined as : - SES-CD total score of 0-2, OR - SES-CD total score of = 4 and at least 2 point reduction from Baseline with no subscore \> 1
Query!
Timepoint [28]
0
0
at Week 52
Query!
Secondary outcome [29]
0
0
Stage 2. Percentage of patients with CS-free clinical remission
Query!
Assessment method [29]
0
0
Percentage of patients achieving CS-free average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item
Query!
Timepoint [29]
0
0
at Week 52
Query!
Secondary outcome [30]
0
0
Stage 2: Percentage of patients with CS-free endoscopic remission
Query!
Assessment method [30]
0
0
For participants taking CS at Baseline, percentage of patients achieving CS-free endoscopic remission
Query!
Timepoint [30]
0
0
at Week 52
Query!
Secondary outcome [31]
0
0
Stage 2: Percentage of patients with CS-free clinical remission
Query!
Assessment method [31]
0
0
For participants taking CS at Baseline, percentage of patients achieving CS-free clinical remission
Query!
Timepoint [31]
0
0
at Week 52
Query!
Secondary outcome [32]
0
0
Stage 2. Percentage of patients with endoscopic response
Query!
Assessment method [32]
0
0
Endoscopic response is described as minimum of 50% decrease from Baseline in SES-CD total score
Query!
Timepoint [32]
0
0
at Week 12
Query!
Secondary outcome [33]
0
0
Stage 2. Percentage of patients with clinical remission
Query!
Assessment method [33]
0
0
Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item (measured by PRO questrionare)
Query!
Timepoint [33]
0
0
at Week 12
Query!
Secondary outcome [34]
0
0
Stage 2. Percentage of patients with endoscopic response and endoscopic remission
Query!
Assessment method [34]
0
0
Endoscopic response is defined as minimum of 50% decrease from Baseline in SES-CD total score Endoscopic remission: - SES-CD total score of 0-2, OR - SES-CD total score of = 4 and at least 2 point reduction from Baseline with no subscore \> 1
Query!
Timepoint [34]
0
0
Endoscopic response at Week 12, endoscopic remission at Week 52
Query!
Secondary outcome [35]
0
0
Stage 2. Percentage of patients with clinical remission
Query!
Assessment method [35]
0
0
Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item (measured by PRO questionnaire)
Query!
Timepoint [35]
0
0
at both Week 12 and Week 52
Query!
Secondary outcome [36]
0
0
Stage 2. Percentage of patients achieving CS-free endoscopic response
Query!
Assessment method [36]
0
0
Endoscopic response is described as minimum of 50% decrease from Baseline in SES-CD total score
Query!
Timepoint [36]
0
0
at Week 52
Query!
Secondary outcome [37]
0
0
Stage 2. Percentage of patients with clinical remission
Query!
Assessment method [37]
0
0
Percentage of patients achieving CS-free clinical remission Clinical remission is defined for a participant to satisfy the following two response thresholds simultaneously: average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND average daily AP subscore of = 1 as assessed on the CDAI AP item.(measured by PRO questionnaire)
Query!
Timepoint [37]
0
0
at Week 52
Query!
Secondary outcome [38]
0
0
Stage 2. Serum concentration of brazikumab
Query!
Assessment method [38]
0
0
Pharmacokinetics: concentration of brazikumab in serum
Query!
Timepoint [38]
0
0
Through Week 68
Query!
Secondary outcome [39]
0
0
Stage 2. Incidence of anti-drug antibodies
Query!
Assessment method [39]
0
0
Immunogenicity: incidence of brazikumab anti-drug antibodies in blood serum
Query!
Timepoint [39]
0
0
Through Week 68
Query!
Secondary outcome [40]
0
0
Stage 2. Exposure-response
Query!
Assessment method [40]
0
0
Derive exposure response model linking primary endpoint to metrics of model predicted individual brazikumab exposures
Query!
Timepoint [40]
0
0
Through Week 68
Query!
Secondary outcome [41]
0
0
Stage 2. Number and percentage of patients with adverse events
Query!
Assessment method [41]
0
0
Number and percentage of patients with reported adverse events
Query!
Timepoint [41]
0
0
Through Week 68
Query!
Secondary outcome [42]
0
0
Stage 2. Percentage of patients with potentially clinically significant changes in laboratory values
Query!
Assessment method [42]
0
0
Percentage of patients with clinically significant changes in hematology, clinical chemistry, urinalysis.
Query!
Timepoint [42]
0
0
Through Week 68
Query!
Secondary outcome [43]
0
0
Stage 2. Percentage of patients with potentially clinically significant changes in vital signs
Query!
Assessment method [43]
0
0
Percentage of patients with potentially clinically significant changes in systolic, diastolic pulse rate
Query!
Timepoint [43]
0
0
Through Week 68
Query!
Secondary outcome [44]
0
0
Stage 2. Percentage of patients with potentially clinically significant changes in physical exams
Query!
Assessment method [44]
0
0
Percentage of patients with potentially clinically significant changes in full physical exams
Query!
Timepoint [44]
0
0
Through Week 68
Query!
Secondary outcome [45]
0
0
Stage 2. Percentage of patients with potentially clinically significant changes in ECGs
Query!
Assessment method [45]
0
0
Percentage of patients with potentially clinically significant changes in 12-lead ECG recordings
Query!
Timepoint [45]
0
0
Through Week 68
Query!
Eligibility
Key inclusion criteria
Inclusion and
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria are the same for both Stage 1 and Stage 2; however, participants enrolled in Stage 1 will not be permitted to enroll in Stage 2.
Inclusion Criteria:
1. At the time of signing the informed consent, the participant must be 18 to 80 years of age, inclusive.
2. A diagnosis of ileal, ileocolonic, or colonic CD with an onset of symptoms for a minimum of 3 months prior to Screening as determined by the investigator based on clinical history, exclusion of other etiologies including infectious causes, and characteristic endoscopic and/or histologic findings.
3. Moderately to severely active CD defined by a CDAI score of 220 to 450 AND; CDAI LSF score = 5 OR CDAI AP score = 2; AND SES-CD of at least 6
4. Participant had an inadequate response or intolerance to intervention with conventional treatment [oral aminosalicylates, oral CS, azathioprine, methotrexate, or 6-mercaptopurine], or prior biological treatment, or demonstrated CS dependence for the treatment of CD. For participants who have previously used biological treatment, a participant may have failed up to 3 biologics that include up to 2 different mechanisms of action.
5. Participants taking 5-aminosalicylates, Oral prednisone (or equivalent), Budesonide, Immunomodulators, Oral antibiotics, Immunomodulators, Probiotics must be at a stable dose.
6. Participant must have the QFT-TB test performed and meet the following TB criteria.
A TB worksheet must also be completed:
1. Participant has no known history of active TB.
2. Participant has no known history of latent TB without completion of an appropriate course of intervention.
3. Meets 1 of the following acceptable TB test results:
i. Negative QFT-TB obtained from central laboratory during Screening, OR ii. For a positive QFT-TB test obtained during Screening from the central laboratory, active TB must be ruled out or treated and negative QFT-TB confirmed by central laboratory OR iii. Indeterminate QFT-TB test obtained during the Screening Period from the central laboratory with ongoing QFT-TB testing as outlined in Appendix G. Participants with an indeterminate QFT-TB test can continue with Screening if they have all of the following:
1. no symptoms/risk factors per TB worksheet provided by the sponsor
2. no known recent exposure to a case of active TB
3. no evidence of active TB on chest x-ray within 8 weeks prior to Screening or during Screening
4. confirmed QFT-TB negative by central laboratory
7 Female participants of childbearing potential must have a negative urine pregnancy test prior to administration of study intervention and must agree to use a highly effective method of birth control (confirmed by the investigator) from randomization throughout the study duration and for at least 18 weeks after last dose of study intervention.
8 Women not of childbearing potential are defined as women who are either permanently sterilized or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned date of randomization without an alternative medical cause.
9 Nonsterilized males who are sexually active with a female partner of childbearing potential must comply with the methods of contraception during treatment and until the end of relevant systemic exposure in the male participant, plus a further 18 weeks.
10 Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
11 Willingness and ability to attend all study visits, comply with the study procedures, read and write in order to complete questionnaires, and be able to complete the study period.
12 Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative.
Complete inclusion criteria are in the study protocol
1. Participant is unable or unwilling to have endoscopic procedures performed during the study.
2. History or current diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, colonic mucosal dysplasia, primary sclerosing cholangitis, or untreated bile acid malabsorption.
3. History of toxic megacolon within 3 months prior to Randomization.
4. Any intra-abdominal surgery, bowel resection, diversion, placement of ostomy or stoma within 3 months prior to Screening. Participants with a draining stoma, ostomy, or extensive colonic resection are excluded irrespective of the time from surgery.
5. Participant has an enterocutaneous or enterovesicular fistula. Participants with other active fistulas, including perianal fistulas, may be considered for enrollment if there is no anticipation for surgery and there is no evidence of active infection (eg, abscess).
6. Bowel perforation during the 6 months prior to Screening or evidence of obstruction within 3 months of Screening.
7. Complications of CD including short bowel syndrome, strictures/stenoses with obstruction or pre-stenotic dilation, or conditions where surgery may be anticipated within 6 months, or other conditions that may confound efficacy evaluations for the study.
8. Participant has any non-passable colonic stenosis/narrowing identified during the qualifying ileocolonoscopy (successful endoscope passage to the caecum with inability to enter the endoscope into the ileum is not covered under this exclusion criterion, and does not require exclusion).
9. Ongoing nutritional dependency for total parenteral nutrition or an elemental diet at Screening.
10. Participant has any of the following related to infections: • Evidence of a recent (within 6 months of Randomization) systemic fungal infection, requiring inpatient hospitalization, and/or antifungal treatment. • Any infection requiring hospitalization or treatment with IV anti-infectives (including antiviral treatment) within 4 weeks of Screening. • Cytomegalovirus or Epstein-Barr virus infection that has not resolved within 8 weeks prior to Screening • Clinically significant chronic infection (eg, osteomyelitis) that has not resolved within 8 weeks of Screening • Nonserious infection requiring oral anti-infectives within 2 weeks prior to randomization must be further discussed with the Study Physician/designee. • Participant has clinical evidence of or suspected to have an abscess during Screening. • Diagnosis of peritonitis or receiving treatment for peritonitis within 8 weeks prior to Screening • Participant has any underlying condition that predisposes participant to infections • Clinically significant active infection or signs/symptoms of infection that has the potential to worsen with immunosuppressive therapy • Signs or symptoms of ongoing infection due to intestinal pathogens
11. Previous allogenic bone marrow transplant or history of organ or cell-based transplantation (eg, islet cell transplantation or autologous stem cell transplantation) with the exception of corneal transplant.
12. Chronic hepatitis B or C infection.
13. Known history of primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, includingHIV infection.
14. Prior history of or current diagnosis of a demyelinating disorder.
15. Participant has received the following treatment: • Adalimumab, certolizumab pegol, infliximab, or golimumab: within 8 weeks prior to Randomization • Vedolizumab or ustekinumab within 12 weeks prior to Randomization • Other prohibited medication, biologic or small molecule treatment within 5 half-lives prior to Randomization • Fecal microbiota transplantation: within 8 weeks prior to Screening ileocolonoscopy
16. Except for ustekinumab, prior exposure to any biologic agent targeting IL-12 or IL-23.
17. Participants who received cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, tacrolimus (FK-506), or tofacitinib within 2 weeks prior to Screening Visit 1.
18. Known history of allergy to the study intervention formulation or any of its excipients or components of the delivery device, or to any other biologic therapy.
19. Participants received more than 1 dose of IV or intramuscular steroids within 2 weeks prior to Screening Visit 1.
20. Participant received topical (rectal) aminosalicylic acid (eg, mesalamine) or topical (rectal) steroids within 2 weeks prior to Randomization.
21. Participant received a Bacille Calmette-Guérin vaccination within 12 months of Randomization or any other live vaccine less than 4 weeks prior to Randomization or is planning to receive any such vaccine over the course of the study.
22. Participant has known or suspected history of chronic use of NSAIDs (defined as at least 3 times per week for more than 3 months; not applicable to daily aspirin use up to 325mg per day) and/or opiates, drug, or alcohol abuse.
23. History of cancer with the following exceptions: (a) A history of basal cell carcinoma and/or squamous cell carcinoma of the skin, with apparent successful curative therapy greater than 12 months prior to Screening (b) Carcinoma in situ of the cervix, with apparent successful curative therapy, greater than 12 months prior to Screening.
24. Clinically significant cardiovascular conditions including recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within 6 months of Screening.
25. Prolonged QTcF interval (QTc >450 msec or QTC >480 for participants with bundle branch block; determined on central ECG), or conditions leading to additional risk for QT prolongation (eg, congenital long-QT syndrome).
26. Clinically significant kidney disease
27. Abnormal laboratory results at Screening
28. Other concurrent medical conditions: Participant has known, preexisting, clinically significant endocrine, autoimmune, metabolic, neurologic, renal, gastrointestinal, hepatic, hematological, respiratory or any other system abnormalities that are not associated with CD and are uncontrolled with standard treatment.
29. Participant is currently enrolled in another investigational device or drug study, or is within 35 days or 5 half-lives, whichever is longer, since ending another investigational device or drug study, or receiving other investigational agent(s)
30. Transfusion of blood, plasma, or platelets within the 30 days prior to Screening.
31. Females who are pregnant, nursing, or planning a pregnancy during the study OR females who are of childbearing potential and do not agree to use a highly effective method of contraception consistently and correctly.
32. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
33. Previous randomization in the present study. . Complete exclusion criteria are in the study protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/12/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/10/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
89
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nevada
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Mexico
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
British Columbia
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Quebec
Query!
Country [21]
0
0
Czechia
Query!
State/province [21]
0
0
Ceské Budejovice
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Horovice
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Hradec Králové
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Olomouc
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Augsburg
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Berlin
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Hamburg
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Kiel
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Minden
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Remscheid
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Ulm
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Budapest
Query!
Country [33]
0
0
India
Query!
State/province [33]
0
0
Bangalore
Query!
Country [34]
0
0
India
Query!
State/province [34]
0
0
Hyderabad
Query!
Country [35]
0
0
India
Query!
State/province [35]
0
0
Jaipur
Query!
Country [36]
0
0
India
Query!
State/province [36]
0
0
Surat
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Haifa
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Jerusalem
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Petah Tikva
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Milan
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Padua
Query!
Country [42]
0
0
Poland
Query!
State/province [42]
0
0
Bydgoszcz
Query!
Country [43]
0
0
Poland
Query!
State/province [43]
0
0
Chojnice
Query!
Country [44]
0
0
Poland
Query!
State/province [44]
0
0
Krakow
Query!
Country [45]
0
0
Poland
Query!
State/province [45]
0
0
Poznan
Query!
Country [46]
0
0
Poland
Query!
State/province [46]
0
0
Rzeszów
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Sopot
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Torun
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Warsaw
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Wroclaw
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Zamosc
Query!
Country [52]
0
0
Russia
Query!
State/province [52]
0
0
Aramil
Query!
Country [53]
0
0
Russia
Query!
State/province [53]
0
0
Moscow
Query!
Country [54]
0
0
Russia
Query!
State/province [54]
0
0
Perm
Query!
Country [55]
0
0
Slovakia
Query!
State/province [55]
0
0
Banská Bystrica
Query!
Country [56]
0
0
Slovakia
Query!
State/province [56]
0
0
Košice
Query!
Country [57]
0
0
Slovakia
Query!
State/province [57]
0
0
Nitra
Query!
Country [58]
0
0
South Africa
Query!
State/province [58]
0
0
Cape Town
Query!
Country [59]
0
0
South Africa
Query!
State/province [59]
0
0
Johannesburg
Query!
Country [60]
0
0
South Africa
Query!
State/province [60]
0
0
Plumstead
Query!
Country [61]
0
0
South Korea
Query!
State/province [61]
0
0
Busan
Query!
Country [62]
0
0
South Korea
Query!
State/province [62]
0
0
Daegu
Query!
Country [63]
0
0
South Korea
Query!
State/province [63]
0
0
Seoul
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Madrid
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Pontevedra
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
Valencia
Query!
Country [67]
0
0
Taiwan
Query!
State/province [67]
0
0
Kaohsiung City
Query!
Country [68]
0
0
Taiwan
Query!
State/province [68]
0
0
Taichung
Query!
Country [69]
0
0
Taiwan
Query!
State/province [69]
0
0
Taipei
Query!
Country [70]
0
0
Ukraine
Query!
State/province [70]
0
0
Kharkiv
Query!
Country [71]
0
0
Ukraine
Query!
State/province [71]
0
0
Kyiv
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Coventry
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
West Bromwich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy
Query!
Trial website
https://clinicaltrials.gov/study/NCT03759288
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Kathy Bohannon
Query!
Address
0
0
AstraZeneca
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP)
Query!
When will data be available (start and end dates)?
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Query!
Available to whom?
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://astrazenecagroup-dt.pharmacm.com/DT/Home
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03759288
Download to PDF